HALETHORPE,
Md., May 14, 2024 /PRNewswire/ -- Fzata, Inc.
is honored to be selected as a finalist to pitch at Start-Up
Stadium during the BIO2024 International Convention, San Diego, CA, June 3-6. BIO will host over
20,000 industry leaders from across the globe. Start-Up Stadium is
designed to provide start-up companies with the opportunity to
engage key members of the investment community, venture
philanthropy groups, strategic partners, and non-dilutive capital
partners at the world's largest biotechnology partnering event.
We are proud that The Maryland Department of
Commerce has selected Fzata to join a delegation of Maryland companies attending BIO2024 and has
provided Fzata with Premier Access to the BIO One-on-One Partnering
system for engagement with potential pharmaceutical strategic
partners and investors.
At BIO2024 Fzata will be seeking strategic
partners for drugs developed from the BioPYM platform including
drug candidates FZ002 for C. diff infection, FZ004 for abdominal
pain, FZ006 for inflammatory bowel disease, and FZ010 for
diabetes/obesity. All four drug candidates have applications in
both human and animal health. FZ002 is Fzata's lead drug candidate
expected to enter clinical trials in 2024. Fzata is also seeking
venture investments to support Company growth. The Company is also
open to co-development with pharmas interested in developing
their drugs in the BioPYM platform.
"We are grateful to the BIO selection committee
and Maryland Commerce for recognizing the great potential of the
BioPYM platform and our lead assets," commented Dr. Zhiyong Yang, Chief Executive Officer of Fzata.
"BioPYM will be a game-changer for both industry and patients in
terms of safety, efficacy and access. Our room-temperature, oral
biologics will drastically improve the way biologics are
manufactured, distributed, stored, and administered."
About Fzata, Inc.: The Company has innovated and
developed a next-generation therapeutics platform called
Biotherapeutic Probiotic Yeast Medicines (BioPYM™) for oral
biologics. Leveraging BioPYM, the Company is developing
proprietary, novel, oral biologic therapies to treat a wide variety
of GI diseases and gut-health axis disorders. BioPYM transforms
probiotic yeast into a micro-factory within the gut, producing
therapeutics right where the disease pathologies occur. The
platform is designed to "plug and play" any gene to make any
therapeutic protein including monoclonal antibodies, multi-specific
antibodies, enzymes, cytokines, and hormones.
For additional Fzata information,
visit www.fzata.com or LinkedIn.
For Investment opportunities, licensing,
co-development, or collaboration inquiries, please contact:
Elizabeth Smith,
PhD, MBA, Chief Business Officer, Fzata
E-mail: Elizabeth_Smith@Fzata.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fzata-is-a-start-up-stadium-finalist-at-bio-2024-302141949.html
SOURCE Fzata, Inc.